Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07625735

MMR Status Modulates the Predictive Value of Lymphatic Invasion for Lymph Node Metastasis in Gastric Cancer

Brief Summary

Lymph node metastasis (LNM) is a key factor influencing treatment decisions and prognosis in patients with gastric cancer. Lymphatic invasion (LI) is an important pathological predictor of LNM and a core component of the eCURA risk scoring system after endoscopic submucosal dissection (ESD) for early gastric cancer. However, whether LI has the same predictive value for LNM across different mismatch repair (MMR) statuses remains unclear. Compared with proficient mismatch repair (pMMR) gastric cancer, deficient mismatch repair (dMMR) gastric cancer has distinct molecular pathological features and an immune-enriched tumor microenvironment. In early gastric cancer, if LI is associated with a lower LNM risk in dMMR tumors than in pMMR tumors, existing LI-based eCURA risk assessment may overestimate LNM risk in patients with dMMR early gastric cancer and consequently affect decisions regarding additional surgery after ESD. Therefore, this study aims to systematically evaluate the impact of MMR status on the association between LI and LNM using upfront-surgery and post-ESD additional-surgery cohorts from our center, and to explore the potential clinical value of MMR status in refining eCURA-based risk stratification for early gastric cancer.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Gastric / Gastroesophageal Junction Adenocarcinoma Lymph Node Metastasis Lymphatic Invasion Lymphatic Metastasis Mismatch Repair Deficient or MSI-High Solid Tumors Neoplasm Metastasis Neoplasms Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms Turcot syndrome

Age range

18 year–95 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Upfront surgery cohort
  • Patients who underwent radical surgery for gastric cancer at Zhongshan Hospital, Fudan University.
  • Patients who did not receive neoadjuvant chemotherapy, radiotherapy, immunotherapy, or other antitumor treatments that may affect the pathological assessment of the primary tumor or lymph node metastasis before surgery.
  • Patients with pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma after surgery, including Siewert type II and III tumors only.
  • Patients with definite pathological assessment of lymphatic invasion and regional lymph node status.
  • Patients with available and definite MMR status.
  • ESD cohort
  • Patients who underwent ESD for gastric cancer at Zhongshan Hospital, Fudan University.
  • Patients with pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma after ESD, including Siewert type II and III tumors only.
  • Patients with complete post-ESD pathological information, including histological type, depth of invasion, tumor size, ulcerative findings, lymphatic invasion status, venous invasion status, horizontal margin status, and vertical margin status.
  • Patients with available and definite MMR status.

Exclusion criteria

  • Upfront surgery cohort
  • Patients with other pathological types, such as gastric squamous cell carcinoma or neuroendocrine carcinoma.
  • Patients who received neoadjuvant treatment before surgery, including chemotherapy, radiotherapy, immunotherapy, targeted therapy, or other systemic antitumor treatments.
  • Patients with missing postoperative pathological information, resulting in inability to determine lymphatic invasion or regional lymph node metastasis status.
  • Patients with missing or indeterminate MMR status.
  • Patients with concurrent malignancies that may interfere with the determination of the origin of lymph node metastasis.
  • ESD cohort
  • Patients with other pathological types, such as gastric squamous cell carcinoma or neuroendocrine carcinoma.
  • Patients with missing post-ESD pathological information that precludes eCURA classification, eCURA risk score calculation, or assessment of lymphatic invasion status.
  • Patients with missing or indeterminate MMR status.

Treatment and study plan

Mismatch repair (MMR) status

Other

Mismatch repair (MMR) status was assessed as part of routine pathological evaluation. Patients were classified as deficient mismatch repair (dMMR) or proficient mismatch repair (pMMR) according to immunohistochemical expression of MLH1, PMS2, MSH2, and MSH6.

Lymphatic invasion status

Other

Lymphatic invasion status was determined from routine pathological reports and classified as LI-positive or LI-negative.

Primary outcomes

  1. Lymph Node Metastasis Rate Among LI-Positive Gastric Cancer Patients

    Time frame: At postoperative pathological assessment, approximately 14 days after upfront surgery

    LI positivity is defined as lymphatic invasion explicitly documented in the pathological report or tumor emboli within lymphatic vessels confirmed by D2-40 immunohistochemistry. LNM is defined as regional lymph node metastasis confirmed by postoperative pathological examination. The LNM rate among LI-positive patients is calculated as the number of patients with LNM divided by the total number of LI-positive patients in the corresponding group.

Secondary outcomes

  1. LI Positivity Rate According to MMR Status

    Time frame: At postoperative pathological assessment, approximately 14 days after upfront surgery

    This outcome evaluates differences in LI positivity rate between patients with dMMR and pMMR gastric cancer. LI positivity rate is calculated as the number of LI-positive patients divided by the total number of patients in each MMR group.

  2. Overall LNM Rate According to MMR Status

    Time frame: At postoperative pathological assessment, approximately 14 days after upfront surgery

    This outcome evaluates differences in overall LNM rate between patients with dMMR and pMMR gastric cancer. Overall LNM rate is calculated as the number of patients with pathologically confirmed LNM divided by the total number of patients in each MMR group.

  3. eCURA Risk Stratification and LI Contribution in the Gastric Cancer ESD Cohort

    Time frame: At pathological assessment of the ESD specimen, approximately 14 days after ESD

    This outcome evaluates differences in eCURA classification, eCURA risk score distribution, and the contribution of LI to the risk score between dMMR and pMMR patients in the gastric cancer ESD cohort. LI contribution is assessed based on its role in eCURA-C2 classification and/or its component score contribution within the eCURA risk scoring system.

  4. LNM Rate Among LI-Positive Patients in the cohort undergoing additional gastrectomy after ESD

    Time frame: At postoperative pathological assessment, approximately 14 days after additional surgery

    This outcome evaluates differences in LNM risk between LI-positive dMMR and pMMR patients with early gastric cancer who underwent additional surgery after ESD. LNM is defined as regional lymph node metastasis confirmed by pathological examination of the additional surgical specimen. LNM rate is calculated as the number of patients with LNM divided by the total number of LI-positive patients in each MMR group.

Study contacts

Contact information is provided by the study sponsor or research team.

Zhaoqing Tang

CONTACT

[email protected]

86-021-64041990

Sponsors and collaborators

Lead sponsor

Shanghai Zhongshan Hospital

Other

Registry information

Official study title

Mismatch Repair (MMR) Status Modulates the Predictive Value of Lymphatic Invasion for Lymph Node Metastasis in Gastric Cancer

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Jun 4, 2026
Registry last updated
Jun 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.